A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Pfizer said last November that it was spinning ... however and recently started a phase 3 trial in dermatomyositis, a rare disease that causes skin rashes and muscle inflammation, can lead to ...

Pfizer has abandoned development of a hemophilia ... Another gene therapy for the rare bleeding disorder was approved last year but has mustered little interest, largely because standard-of ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Earlier this year, Pfizer had revealed data from the therapy's late-stage study, which showed that the treatment reduced the number of annual bleeding episodes in patients with the rare disorder.

Reviewed by David Kindness Pfizer Inc. (PFE) is a global biopharmaceutical company based in New York. The company makes money ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

On December 1, Pfizer became the first big pharma to commit to take to market a late-stage biologic drug produced in plant cells. It acquired rights to taligurase alfa, a form of the enzyme ...